×

What are you searching for?




Press Release

4 Min read

Cancer Cachexia Market to Grow at 4.9% CAGR during 2021-2029, Owing to Technological Advancement in the Treatment of Cancer Cachexia, Reports Absolute Markets Insights

Published On 31 Aug 2021 06:47 AM


SHARE THIS ARTICLE  


A devastating complication of cancer, cachexia is an important cause of disability and mortality for which, so far medical science does not have any approved treatment. Although cachexia can be caused by diverse medical conditions, usually it is associated with end-stage cancer that is known as cancer cachexia. Cachexia wastes both adipose tissue as well as skeletal muscle. Occurring in many conditions, it is common with many uncontrolled cancers. Some cancers, especially gastric cancer and pancreatic cancer, can cause profound cachexia where the affected patients may lose 10 to 20% of their body weight.

Request a sample [email protected] https://www.absolutemarketsinsights.com/request_sample.php?id=880

A report published by International Agency for Research on Cancer (IARC) in DEC 2020, globally, 1 in 5 people developed cancer during their lifetime. The report highlighted that 1 in 8 men and 1 in 11 women die from cancer every year. According to a study, among 14 separately analyzed cancer types, the prevalence of cancer cachexia in the United States ranged between 11,300 and 92,000 patients, across all age groups. A new study carried out at Karl Landsteiner University of Health Sciences in Krems (KL Krems) recently found that weight loss and muscle wasting in cancer cachexia patients had a deleterious effect on bone metabolism. AIkido Pharma Inc. received a Notice of Allowance from the U.S. Patent and Trademark Office for its technology related to the use of novel and proprietary central nervous system (CNS) homing peptides. Now AIkido Pharma Inc. can use psilocybin for the therapeutic treatment of neuroinflammatory disease in cancer cachexia patients.

The most important factor that is driving the global cancer cachexia market is rising prevalence of cancer. Cachexia is affecting patients with both, localized cancer as well as metastatic cancer. Clinical attention is not always easily available. The other important factors affecting the market growth include increasing investment from market players in the research & development activities for the development of novel therapeutics in the treatment of cancer cachexia, and lastly, government support for cancer research.

Technological advancement extends profitable opportunities for the growth of global cancer cachexia market over the forecast period. Machines are required to scan and check the internal organs affected from cancer cachexia. The technological advancement aided in the production of new machines suitable for this purpose. According to a study, changes in the nutritional status and weight loss during hospitalization were largely reported in some populations during a study, but it was not completely explored in COVID-19 patients. However, the symptoms associated with the conditions of China-originated coronavirus did lead to nutritional status deterioration, causing cancer cachexia among many COVID-19 patients. It remains to be seen if the treatment meant to cure coronavirus can cure some symptoms of cancer cachexia. Hence, investments and research efforts in this direction is anticipated to advance the growth of global cancer cachexia market over the future years.

Enquiry Before [email protected] https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=880

Key Findings of the Report:

  • The global cancer cachexia market was valued at US$ 2117.60 Mn in 2020 growing at a CAGR of 4.9% over the forecast period (2021 – 2029).
  • Combinantion therapy treatment is gaining traction in the global cancer cachexia market. The concept of customized fitness regime and functional fitness have popularized the concept of combination therapies which goes beyond medicines and incorporates diet and exercises. For instance, along with the conventional novel pharmaceutical agents, such as ghrelin, medroxyprogesterone, megestrol, and omega-3-fatty acid amongst others, diet modification and exercise routine supplement the combination therapy.
  • The application of cancer cachexia was observed to be highest for weight loss stabilization amongst patients in 2020. Cachexia causes extreme weight loss as well as muscle wasting to the patients. Medroxyprogesterone acetate (MPA) can increase appetite and food intake, while also ensuring stabilization of body weight. There is an increasing availability of health supplements and energy drinks that are high in protein, energy, lipid, along with being low in carbohydrate. Protein prevents the loss of muscle mass. Such energy drinks also help the patients who have insulin resistance. Apart from nutrition, oncologists also prescribe medical therapies that can increase body weight and lean body mass. Non-steroidal anti-inflammatory drugs, megestrol acetate, oxandrolone, and tetrahydrocannibinol are also helping patients to stabilize body weight and thus, contributing to the market growth.
  • In 2020, North America was the biggest regional market in the global cancer cachexia market due to the high burden of cancer and cancer cachexia along with the presence of many drug manufacturers that play an important role in global cancer cachexia market. The advancement in the medical sector that is beneficial to the care for cancer patients is also contributing to the growth in this region. According to the estimates of Globocan 2020, there were around 195,499 new cases of cancer (including cancer cachexia) in Mexico and approximately 90,222 deaths were recorded. U.S.-based Aveo Oncology developed AV-380, which is a first of its kind potent, and humanized inhibitory antibody targeting GDF15, that is helpful for the treatment of cancer cachexia. The Phase 1 clinical study on AV-380 was scheduled for the first quarter of 2021. The rising number of geriatric population along with an increasing healthcare spending in North America along with the availability of advanced healthcare infrastructure are other factors boosting the market growth in this region.
  • Some of the major players operating in the global cancer cachexia market are Actimed Therapeutics, Anuh Pharma Ltd., Aphios Corporation, Aveo Oncology, Fresenius Kabi, Helsinn Group, Merck KGaA, NGM Biopharmaceuticals, Pfizer Inc., R&D Systems Inc., Symbiotec Pharma Lab Pvt. Ltd., and Tetra Bio-Pharma amongst others.

Request for [email protected] https://www.absolutemarketsinsights.com/request_for_customization.php?id=880

Global Cancer Cachexia Market:

  • By Treatment
    • Corticosteroids
    • Progesterones 
    • Ghrelin (Gastric Peptide Hormone)
    • Combination Therapy
    • Others
  • By Application
    • Appetite Stimulation
    • Weight Loss Stabilization
    • Others
  • By Distribution Channel
    • Hospitals & Clinics
    • Retail Pharmacies
    • Others
  • Regions
    • North America
      • U.S.
      • Canada
      • Mexico
      • Rest of North America
    • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Nordic Countries
        • Denmark
        • Finland
        • Iceland
        • Sweden
        • Norway
      • Benelux Union
        • Belgium
        • The Netherlands
        • Luxembourg
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • New Zealand
      • Australia
      • South Korea
      • Southeast Asia
        • Indonesia
        • Thailand
        • Malaysia
        • Singapore
        • Rest of Southeast Asia
      • Rest of Asia Pacific
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • Egypt
      • Kuwait
      • South Africa
      • Rest of Middle East & Africa
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America

For More Information [email protected] https://www.absolutemarketsinsights.com/reports/Cancer-Cachexia-Market-2021---2029-880


SHARE THIS ARTICLE  

Press Release Provided By: Absolute Markets Insights